BROS vs TSLA

The Advanced Deterministic Scorecard reveals a mixed financial profile: the Piotroski F-Score of 4/9 indicates borderline stability, while the absence of an Altman Z-Score prevents a full distress risk assessment. Despite strong revenue and earnings growth, elevated valuation multiples—P/E of 124.43 and Price/Book of 11.80—suggest the stock is pricing in aggressive future expectations. Profitability margins and ROE are above sector averages, but insider selling worth over $600M in the last six months raises concern about confidence at the top. Analysts maintain a strong_buy consensus, yet technical trend and recent price performance show weakness, indicating potential near-term headwinds.

Tesla's deterministic health is marginally stable with a Piotroski F-Score of 4/9, but the valuation is fundamentally decoupled from financial performance. The stock trades at a massive premium to its Graham Number ($23.07) and Intrinsic Value ($7.56), while exhibiting negative revenue growth (-3.10%) and a severe collapse in earnings growth (-60.60%). With zero earnings beats in the last four quarters and bearish insider activity, the current price is supported by sentiment rather than data.